

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that Shijiazhuang No. 4 Pharmaceutical Co., Ltd., a wholly subsidiary of the Company, has obtained the approval for drug production and registration for Moxifloxacin Hydrochloride Tablets (0.4g) from the National Medical Products Administration of China, being regarded as passing the consistency evaluation.

Moxifloxacin Hydrochloride Tablets (0.4g) is under type 4 chemical new drug. Moxifloxacin is a 4th generation quinolone bactericide and a new generation broad-spectrum antibiotic, and is mainly used in treatment of a variety of bacterial infections including pneumonia, tuberculosis, endocarditis, conjunctivitis (pink eye) and respiratory tract infection.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 11 January 2022

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.